The most common side effects of Ozempic (semaglutide) are gastrointestinal: nausea, vomiting, diarrhea, and constipation. A meta-analysis of randomized trials found that roughly one in four people taking a GLP-1 receptor agonist experienced nausea, while about one in eight had diarrhea. But the side-effect profile extends well beyond an upset stomach, touching the gallbladder, pancreas, eyes, skin, hair, and possibly mood in ways that deserve a closer look.
Digestive Problems Are the Headliner
Ozempic works partly by slowing how fast your stomach empties, which helps control blood sugar and appetite. That same mechanism is also why so many people feel queasy, especially early on. In a large pharmacovigilance analysis of FDA adverse-event reports for semaglutide, the most frequently reported gastrointestinal events were nausea, vomiting, diarrhea, constipation, and abdominal pain, in that order.1PubMed Central. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system A separate meta-analysis of randomized controlled trials put numbers on the rates: nausea affected about 23% of patients, diarrhea about 13%, vomiting about 9%, and constipation around 7%. All of those rates were roughly two to four times higher than placebo.2PubMed. Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials
For most people, these symptoms are worst during the first few weeks and fade as the body adjusts. But for a small subset, the slowed stomach emptying crosses into something more disruptive. Case reports have documented gastroparesis, a condition where the stomach essentially stops moving food along at a functional pace, in patients on semaglutide. The drug stimulates GLP-1 receptors that regulate gastric motility, and in susceptible individuals, this can push normal slowing into outright stalling.3PubMed Central. Tendency of Semaglutide to Induce Gastroparesis: A Case Report Gastroparesis is rare, but worth knowing about if you develop persistent bloating, early fullness, or vomiting that does not ease up after the first month or two.
Gradual Dose Increases Make a Real Difference
Ozempic’s standard prescribing schedule ramps the dose up over eight weeks, but a pilot trial tested whether going more slowly, over 16 weeks, could reduce digestive side effects without sacrificing results. The findings were encouraging. Only about 2% of patients on the slower schedule dropped out because of gut symptoms, compared with 19% on the standard eight-week ramp. Nausea was reported by about 45% in the flexible group versus 64% in the standard group, and the number of days people actually felt nauseous was cut roughly in half. Blood-sugar control and weight loss were similar in both groups at the end.4Diabetes Care. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events If you are starting Ozempic and dreading the nausea, asking your prescriber about a more gradual titration is a conversation worth having.
Gallbladder and Pancreas Risks
Beyond the everyday stomach symptoms, there are two organ-level concerns that carry more serious implications: the gallbladder and the pancreas.
A systematic review and meta-analysis of 76 randomized trials found that GLP-1 receptor agonists as a class raised the risk of gallbladder and biliary diseases by about 37% compared with placebo. That includes gallstones, cholecystitis (gallbladder inflammation), and other biliary problems. The risk was even steeper when the drugs were used specifically for weight loss rather than diabetes, roughly doubling.5PubMed Central. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases There are two likely contributors. First, GLP-1 receptor agonists appear to inhibit gallbladder motility and delay gallbladder emptying, which can set the stage for stones to form. Second, rapid weight loss itself is a well-known trigger for gallstone disease. Higher doses, longer treatment durations, and weight-loss indications all amplified the risk.6PubMed Central. Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations
Pancreatitis is rarer but more alarming. The meta-analysis of GLP-1 receptor agonist trials found pancreatitis occurred in about 1% of patients, at roughly twice the rate seen with placebo.2PubMed. Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials Most cases resolve with supportive care, but severe outcomes have been reported. One documented case involved fatal acute pancreatitis after four years of GLP-1 receptor agonist use, with the episode occurring shortly after a dose increase. The patient had none of the usual pancreatitis risk factors like heavy alcohol use or gallstones, which strengthened the suspected link to the medication.7PubMed Central. Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use Severe abdominal pain radiating to the back, especially around a dose change, warrants immediate medical attention.
A Possible Link to a Rare Eye Condition
One of the more unexpected findings in semaglutide research involves a rare eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. It is essentially a sudden loss of blood flow to the optic nerve, causing painless vision loss. A study at a single U.S. center reported a substantially elevated risk among semaglutide users, particularly in those who were overweight or obese, where the cumulative incidence over three years was about 6.7% for semaglutide users versus under 1% for a comparison group.8JAMA Ophthalmology. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide A larger Danish cohort study covering over 400,000 people with type 2 diabetes found roughly double the incidence rate with semaglutide exposure, though the absolute numbers were still small.9PubMed Central. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
The picture gets more complicated, though. A recent systematic review and meta-analysis pooling available evidence graded the certainty as “very low” to “low.” The pooled odds ratio was not statistically significant across all analyses, and removing one influential study shifted results meaningfully, suggesting the signal is fragile. The association appeared stronger among people with type 2 diabetes than among those using semaglutide for weight loss alone.10PubMed. Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis This is a space where the evidence is still being sorted out. NAION is genuinely rare, so even modest risk increases are hard to pin down in studies. If you have pre-existing risk factors for NAION, such as sleep apnea, small optic disc anatomy, or cardiovascular disease, it is worth flagging this with your eye doctor.
Changes in Body Composition
Weight loss on Ozempic is not purely fat loss, and the ratio matters. A dedicated body-composition study of semaglutide-treated patients found that total fat mass dropped by about 19% over 12 months, while lean mass fell by about 3 kilograms in the first seven months and then stabilized. The proportion of lean mass relative to total body weight actually went up over the treatment period.11PubMed Central. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study A separate study looking at regional body composition found that roughly 70% of the total weight lost was fat and about 30% was muscle.12Metabolism and Target Organ Damage. Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
Losing some muscle during any significant weight loss is normal, not unique to Ozempic. But the speed and magnitude of Ozempic-driven weight loss can make it more pronounced, particularly for older adults or anyone who was already under-muscled. Resistance training and adequate protein intake during treatment are the standard countermeasures, and some clinicians consider them essential rather than optional when prescribing semaglutide.
The “Ozempic Face” Phenomenon
Rapid facial fat loss on semaglutide has earned its own informal name. The hollowed, gaunt look sometimes called “Ozempic face” is not a medically recognized diagnosis, but it reflects a real cosmetic consequence: when fat pads in the cheeks, temples, and around the eyes shrink quickly, the face can look sunken and prematurely aged. The underlying drivers are loss of both fat and collagen support, along with sagging skin that has not had time to contract.13Dermatological Reviews. Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology This effect is more visible in people who lose weight rapidly and in those over 40, when skin elasticity is already declining. It has driven a surge in demand for dermal fillers and other cosmetic procedures among semaglutide users.
Hair Loss
Hair shedding on Ozempic follows a pattern familiar to dermatologists: telogen effluvium, where a stressor pushes a large number of hair follicles into their resting phase at once, causing diffuse thinning a few months later. Rapid weight loss and reduced caloric intake are the likely triggers, not necessarily the drug molecule itself.14JAAD Reviews. Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms A systematic review found that hair loss with semaglutide appeared dose-dependent: doses under 2 mg per week were rarely implicated, while higher doses used for obesity treatment showed up more often in reports. Women were disproportionately affected.15PubMed Central. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling The shedding typically improves once weight stabilizes and nutritional intake recovers, but that can take months, and the interim thinning catches people off guard.
Heart Rate, Blood Sugar, and Kidneys
A modest increase in resting heart rate is a documented effect of GLP-1 receptor agonists. A 12-week study using wearable devices found that semaglutide users saw their resting heart rate rise by about 3 beats per minute on average, mediated by shifts in autonomic nervous system balance.16PubMed. Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference For most people this is trivial, but if you have a pre-existing arrhythmia or heart condition, it is worth monitoring.
Hypoglycemia, or dangerously low blood sugar, is uncommon with Ozempic when used alone because its insulin-stimulating effect is glucose-dependent, meaning it ramps down as blood sugar normalizes. But the risk climbs when Ozempic is combined with sulfonylureas or insulin, which push blood sugar down through different mechanisms.17PubMed Central. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists If you take multiple diabetes medications, your prescriber may need to adjust the other drugs when adding Ozempic.
Kidney injury is another downstream consequence of the GI side effects rather than a direct toxic effect of the drug. Severe nausea, vomiting, and diarrhea can lead to dehydration, and dehydration can cause acute kidney injury, especially in people who already have some degree of reduced kidney function. Patients who develop significant GI symptoms should have their kidney function checked, and the medication may need to be stopped if kidney markers worsen.18PubMed Central. Acute Kidney Injury Associated With Semaglutide
Mental Health Signals
Whether semaglutide affects mood and psychiatric health is one of the more contested areas of its safety profile. A large observational study comparing GLP-1 receptor agonist users to non-users found roughly double the hazard for depression, anxiety, and suicidal ideation or attempts. The Ozempic-specific group showed about a 2.4-fold increase in suicidal ideation or attempts compared with non-users.19Scientific Reports. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy A separate analysis of the FDA’s adverse event database found significant disproportionality signals for semaglutide in both depression and suicide/self-injury events, with the strongest signals in people aged 18 to 64.20PubMed. Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database
These are observational findings, and they come with serious caveats. People with obesity already have higher baseline rates of depression and anxiety, and the act of seeking and starting a new medication may itself be associated with increased healthcare engagement and therefore increased psychiatric diagnosis. Pharmacovigilance databases capture reports, not proven causation. Still, the European Medicines Agency has investigated these signals, and they are worth being aware of. If you notice new or worsening mood symptoms after starting Ozempic, bring them up with your prescriber rather than assuming they are unrelated.
Injection Site Reactions and Rare Allergic Responses
Because Ozempic is a subcutaneous injection, local reactions at the injection site are common. These usually look like redness, mild swelling, or itching and are seen in up to about 20% of users. Delayed hypersensitivity reactions, showing up 24 to 48 hours after an injection with itchy plaques and, in rare cases, systemic symptoms like breathing difficulty, have also been reported. Urticaria (hives) appears in the literature as well, though it is uncommon.21Skin Appendage Disorders. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications Rotating injection sites is standard advice. Any reaction that involves breathing trouble or widespread hives is a reason to seek immediate care.
Thyroid Cancer and the Black Box Warning
Ozempic carries an FDA black-box warning about the risk of thyroid C-cell tumors, based on rodent studies where semaglutide caused thyroid tumors in rats and mice. This finding led to a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or a genetic syndrome called MEN 2. But the relevance to humans has been questioned from the start, because human thyroid tissue has far fewer GLP-1 receptors than rodent thyroid tissue. A systematic review covering ten studies with large sample sizes found that thyroid cancer incidence among semaglutide users was very low, with isolated cases each making up less than 1% of the study populations, suggesting no significant risk.22PubMed Central. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity The black-box warning remains because it cannot be entirely ruled out in long-term use, but the human data so far has been reassuring.
What Happens When You Stop
Ozempic’s side effects go away when you stop, but so do most of its benefits. In the STEP 1 trial extension, participants who discontinued semaglutide after 68 weeks regained about two-thirds of the weight they had lost within the following year. Cardiometabolic markers like blood pressure and cholesterol followed a similar pattern.23PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension This is not really a “side effect” in the traditional sense, but it is arguably the most important thing to understand about the drug’s profile: obesity is a chronic condition, and semaglutide manages it rather than cures it. Stopping tends to mean returning toward your starting point.
Surgical Anesthesia and Residual Stomach Contents
If you are on Ozempic and facing surgery, your anesthesiologist will want to know. Because the drug slows gastric emptying, there is a concern that your stomach may still contain food or liquid when you go under anesthesia, raising the theoretical risk of aspiration, where stomach contents enter the lungs. The American Society of Anesthesiologists has flagged this in its guidelines. A systematic review of the evidence found that most studies did show increased residual stomach contents in GLP-1 receptor agonist users, but evidence linking that to an actual increase in aspiration or regurgitation events was inconsistent.24PubMed Central. Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks Many surgical centers now ask patients to hold their GLP-1 receptor agonist for a week or more before elective procedures, though recommendations vary. If surgery is planned, discuss the timing with both your prescriber and the surgical team.
Effects on Alcohol and Reward Processing
An effect that does not appear on the prescribing label but gets mentioned frequently in patient forums: many Ozempic users report a reduced desire for alcohol. This is consistent with preclinical research showing that GLP-1 acts in the brain to modulate reward pathways. Animal studies have demonstrated that GLP-1 receptor agonists decrease alcohol intake, reduce motivation to drink, and may even prevent relapse.25Endocrinology. GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder Human clinical trials are underway, and early-phase results look promising. Whether this reward dampening extends to food enjoyment, interest in hobbies, or other pleasures is less clear and harder to measure, but anecdotal reports from users describing a kind of emotional flatness about food are common enough to take seriously as a lived experience, even if it has not been formally quantified yet.
Diabetic Eye Disease
People with type 2 diabetes sometimes worry that rapid blood sugar improvement could worsen diabetic retinopathy, a pattern seen with insulin in the past. A study at a tertiary care center compared retinopathy outcomes in GLP-1 receptor agonist users against another class of diabetes drug users and found no statistically significant difference in worsening. Clinical worsening rates were around 2-3% in both groups.26PubMed Central. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center This is one area where the early concern has not been borne out in the data so far, though people with advanced retinopathy should still be monitored closely during any treatment that lowers blood sugar quickly.